Gryphon Financial says investors who want to keep their biotech investments protected during the turbulent economic climate should invest in biotech exchange-traded funds.
Gryphon Financial says investors who want to keep their biotech investments protected during the turbulent economic climate should invest in biotech exchange-traded funds.
The firm says it has experienced impressive gains so far this year in the biotech sector.
Biotech stocks have consistently outperformed the broader market, but this trend could change depending on what lawmakers decide.
A partner at Gryphon Financial says: "Our top traders are known for hand-picking the winning trades, especially in the volatile biotech sector. After a lot of debate, Gryphon Financial is going to continue to capitalise on biotech companies by investing in ETFs. This is just until the healthcare reform outlook clears up."
